1. 13q deletions in lymphoid malignancies
- Author
-
Mats Heyman, Eugene R. Zabarovsky, Omid Rasool, Gunnar Juliusson, Natalia Nikiforova, Mats Merup, Yie Liu, Gösta Gahrton, Ruth Detlofsson, Monica Hermanson, Dan Grandér, Stefan Söderhäll, Xiushan Wu, Charles H.C.M. Buys, Stefan Einhorn, and N. K. Yankovsky
- Subjects
Pathology ,medicine.medical_specialty ,Lymphoma, B-Cell ,Lymphocyte ,Chronic lymphocytic leukemia ,Molecular Sequence Data ,Immunology ,Locus (genetics) ,DNA, Satellite ,Biology ,Lymphoma, T-Cell ,Polymerase Chain Reaction ,Biochemistry ,Cell Line ,law.invention ,immune system diseases ,law ,hemic and lymphatic diseases ,Acute lymphocytic leukemia ,Tumor Cells, Cultured ,medicine ,Humans ,Leukemia-Lymphoma, Adult T-Cell ,Polymerase chain reaction ,DNA Primers ,Base Sequence ,Chromosomes, Human, Pair 13 ,Genetic Carrier Screening ,Hybridization probe ,Homozygote ,Chromosome Mapping ,Cell Biology ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Burkitt Lymphoma ,Candidate Tumor Suppressor Gene ,Lymphoma ,medicine.anatomical_structure ,Cancer research ,Chromosome Deletion ,DNA Probes - Abstract
Previous studies have indicated that a candidate tumor suppressor gene resides telomeric of the RB1 gene at 13q14, a region that is commonly deleted in B-cell chronic lymphocytic leukemia (B-CLL). In this study, we have evaluated the frequency and minimal region of overlap for 13q deletions in malignant cells from various lymphoid neoplasms. We observed losses at 13q14 in 33/75 (44%) B-CLL cases, four of 16 (25%) non-Hodgkin's lymphoma (NHL) cases, eight of 29 (28%) patients with acute lymphocytic leukemia (ALL), and one of 15 T-cell lines. In some ALL cases, inactivation of the RB1 gene is suggested as the important event in the 13q deletions. The most commonly deleted marker in CLL and NHL was D13S319, between RBkpt and the D13S25 loci. Homozygous deletions of this marker were observed in 10 of 75 B-CLL cases, in six of which the homozygous deletions included only the D13S319 locus. Our data suggest that 13q deletions are common in lymphoid neoplasms, and that deletion of a candidate tumor suppressor gene(s) in the vicinity of the D13S319 marker is a tumorigenic event in these diseases.